#Israel #Compugen #Holon #COM701 #OvarianCancer

Compugen to Present Pooled Analysis of COM701

Compugen Ltd., a clinical-stage company specializing in cancer immunotherapy, is set to present a pivotal pooled analysis related to its investigational drug COM701 at the upcoming European Society of Medical Oncology (ESMO) conference in Berlin on October 18, 2025. This analysis consolidates data from previous Phase 1 clinical trials focused on patients with platinum-resistant ovarian cancer, a condition that poses significant treatment challenges due to limited effective therapies.

Background on COM701 and the Study

The pooled analysis encompasses data from 60 evaluable patients who participated in earlier trials of COM701. It aims to characterize the clinical benefit derived from this novel treatment, including progression-free survival metrics, which are crucial for assessing drug efficacy. This research is especially relevant given that patients with platinum-resistant ovarian cancer often face grim prognoses and limited options.

Dr. Oladapo Yeku from Harvard Medical School, who will present the findings, emphasized that the results from the pooled analysis indicate that COM701 is not only well-tolerated but also shows consistent and durable responses, particularly in patients without liver metastases. This subgroup is of particular interest, as these patients typically exhibit lower disease burdens and a less immunosuppressive microenvironment, which may enhance the drug's effectiveness.

The findings serve as critical support for the ongoing MAIA-ovarian trial, which is investigating the use of COM701 as a maintenance therapy in the earlier treatment settings of platinum-sensitive ovarian cancer. Dr. Yeku expressed optimism about discussing these findings in detail at ESMO, highlighting their potential implications for altering treatment paradigms in ovarian cancer care.

Addressing Gaps in Treatment

Eran Ophir, CEO of Compugen, expressed concerns regarding the significant care gaps for women who respond to chemotherapy but are deemed ineligible for additional maintenance therapy. He noted that these patients often have less compromised immune systems, presenting an opportunity to leverage COM701's unique mechanism of action to improve progression-free survival outcomes.

Current efforts are concentrated on the MAIA-ovarian trial, where COM701 monotherapy is examined as a maintenance treatment for relapsed platinum-sensitive cases. An interim analysis is anticipated once data from approximately 60 trial participants is collected, with results expected by the end of 2026. The trial sites are operational in the U.S., Israel, and now expanding in France, in collaboration with the prestigious ARCAGY-GINECO oncology cooperative group, known for its contributions to ovarian cancer research.

Future Directions

The ESMO 2025 event is not only an opportunity for Compugen to showcase its findings but also a platform for other innovative treatments in oncology, including collaborations with large pharmaceutical partners that are exploring Fc-reduced TIGIT programs. AstraZeneca, in particular, is expected to present data that leverages components derived from Compugen's pipeline.

In conclusion, Compugen's commitment to advancing cancer treatment through its predictive AI-driven discovery platform positions it at the forefront of innovative therapies targeting complex oncological conditions like ovarian cancer. As the company navigates regulatory landscapes and clinical development pathways, their work continues to hold promise for improving outcomes for patients who desperately need new therapeutic options.